[Studies of sustained release cephalexin (S-6437) in pediatrics (author's transl)]. 1977

K Saito, and K Ubukata, and M Konno

S-6437 is granule of sustained-release cephalexin which is prepared as longer acting cephalexin. Each gram of the granule contains 200 mg of cephalexin. Absorption and excretion study of this preparation was performed in 8 patients (3 school children, 3 infants and 2 babies). Mean blood levels of cephalexin following a single oral administration of 25 mg/kg in the school children, for instance, were 1.73, 2.47, 3.11, 2.28, 3.84 and 2.86 mcg/ml at 0.5, 1.0, 2.0, 4.0, 6.0 and 8.0 hours, respectively. Fifty-two patients with acute respiratory tract infections were treated with this preparation and out of the 52, 33 were evaluable cases. The daily dose used was 50 mg/kg divided in two doses. Of the 33 patients 29 responded to this preparation showing 87.8% of effectiveness. Four patients who did not respond were 1 with acute pharyngitis, 2 with acute tonsillitis, and 1 with acute bronchitis. No severe side effects due to this preparation were observed.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002506 Cephalexin A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,Cefalexin,Cephalexin Dihydride,Cephalexin Hemihydrate,Cephalexin Hydrochloride,Cephalexin Monohydrate,Cephalexin Monohydrochloride,Cephalexin Monohydrochloride, Monohydrate,Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer,Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer,Cephalexin, (6R-(6alpha,7beta))-Isomer,Cephalexin, Monosodium Salt,Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer,Ceporexine,Palitrex
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Saito, and K Ubukata, and M Konno
September 1977, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
September 1977, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
February 1978, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
November 1977, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
November 1977, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
September 1977, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
December 1977, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
November 1977, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
September 1977, The Japanese journal of antibiotics,
K Saito, and K Ubukata, and M Konno
October 1977, The Japanese journal of antibiotics,
Copied contents to your clipboard!